LifeStance Health Group Inc. Common Stock vs Twist Bioscience Corp — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.42 (market cap $4.58B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.2× LifeStance Health Group Inc. Common Stock's market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 1 Days and Twist Bioscience Corp for 27 Days on average.
| LFST | TWST | |
|---|---|---|
Market Cap | $4.58B | $10.08B |
Volume | 2,356,698 | 4,229,037 |
Sector | Health | Health |
52-Week High | $13.38 | $205.00 |
52-Week Low | $4.81 | $25.45 |
Typical Hold Time | 1 Days | 27 Days |
Enterprise Value | $4.82B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →